Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this study was to evaluate the efficacy of erlotinib for treating advanced non-small cell lung cancer by carrying out a pooled analysis of randomized controlled trials that compared erlotinib-based regimens with other agentbased regimens between January 1997 and 2011. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. Fourteen trials including 7974 patients were identified. As first-line therapy was compared with chemotherapy, there was a similar ORR [OR: 0.33; 95% confidence interval (CI): 0.64-17.36; P = 0.15], but decreased PFS [hazard ratio (HR): 1.55; 95% CI: 1.24-1.93; P < 0.01] and OS (HR: 1.39; 95% CI: 0.99-1.94; P = 0.05). As maintenance therapy was compared with placebo, erlotinib-based regimens significantly increased ORR (OR: 0.47; 95% CI: 0.31-0.70; P < 0.01), prolonged PFS (HR: 0.71; 95% CI: 0.60-0.83; P < 0.01), but did not improve OS (HR: 0.87; 95% CI: 0.68-1.11; P = 0.22). As second/third-line therapy was compared with placebo, erlotinib-based regimens also significantly increased ORR (OR: 0.10; 95% CI: 0.02-0.41; P < 0.01), prolonged PFS (HR: 0.61; 95% CI: 0.51-0.73; P < 0.01), and improved OS (HR: 0.70; 95% CI: 0.58-0.84; P < 0.01). However, as second/third-line therapy was compared with chemotherapy, the outcomes were similar between the two arms. When compared with PF299804, there was a decreased ORR (OR: 3.87; 95% CI: 1.27-11.81; P = 0.02), and shortened PFS (HR: 0.58; 95% CI: 0.49-0.95; P = 0.02). Meanwhile, erlotinib-based regimens showed no significant difference in adverse events, except for diarrhea, rash, and anemia. Erlotinibbased regimens significantly increased ORR and improved PFS as a first-line maintenance therapy or as a second/third-line therapy when compared with placebo.
Introduction
Lung cancer is the major cause of cancer deaths worldwide, and the majority of new cases belong to the advanced non-small cell lung cancer (NSCLC) catagory [1] . The standard first-line treatment for the advanced NSCLC is a platinum-based two-drug combination regimen [2] . However, no doublet regimen has been proved superior, and survival outcomes remained poor (median survival is 7.4-8.1 months; 1-year survival rate is 28-47%) [3] [4] [5] . Thus, the development of more effective therapy remains challenging. The development of agents that target the epidermal growth factor receptor (EGFR) signal transduction pathways has provided a class of novel targeted therapeutic agents.
The EGFRs have been shown to play a significant role in tumorigenesis, with up to 80% of NSCLC expressing EGFR [6, 7] . Overexpression of EGFR is associated with advanced disease and poor survival [8] . Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, New York, USA) is a highly potent reversible HER1/EGFR tyrosine kinase inhibitor that has shown significant antitumor activity in preclinical studies [9] . The antitumor activity with single-agent erlotinib has been proved by phase I/II studies in previously treated patients [10] . In a large randomized, double-blind, placebo-controlled phase III trial in previously treated patients with an advanced NSCLC, erlotinib significantly prolonged survival versus placebo [6.7 vs. 4.7 months; hazard ratio (HR): 0.70; P < 0.001], delayed disease progression, and delayed worsening of disease-related symptoms [11] . The most common adverse events with single-agent erlotinib consisted of mild/moderate rash and diarrhea. However, this is the only phase III trial that has shown prolonged survival with an EGFR inhibitor in an advanced NSCLC. In other phase II and III trials, erlotinib-based regimens did not prove to be superior to other agent-based regimens.
Several randomized controlled clinical trials comparing erlotinib-based regimens with other agent-based regimens in the treatment of advanced NSCLC have been proceeding, and nine of them have reported results. On the basis of these data, we conducted a pooled analysis to assess the efficacy and safety of erlotinib in patients with advanced NSCLC.
Materials and methods

Literature search
The aim of this pooled analysis was to review all published and reported randomized controlled trials (RCTs) comparing the erlotinib-based regimens with other agent-based regimens. Both published and unpublished trials reported between January 1997 and 2011 were identified through a computer-based search of the PubMed database and from abstracts from the past 12 conferences of the American Society of Clinical Oncology and from the past 12 conferences of the European Society for Medical Oncology. The search strategy included the following keywords variably combined: advanced or metastatic, non-small cell lung cancer or NSCLC, Erlotinib, or Tarceva. In addition, we searched trial registries and conference proceedings. We also examined reference lists of original articles, and contacted original trialists for possible unpublished trials. The deadline for trial inclusion was 31 January 2011.
Inclusion and exclusion criteria
The aim of this analysis was to evaluate objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and relevant grade 3/4 adverse events. If erlotinib alone or based combination therapy was included in a RCT, it was considered to be eligible. Inclusion criteria for the trails were as follows: (a) patients were randomly assigned to treatment; (b) erlotinib or based combination regimen was compared with other agent or based combination regimen without confounding by other agents or interventions; and (c) only patients with diagnosis of advanced NSCLC were included. Trials with missing adequate statistical analysis information were also excluded.
Validity assessment
Assessment of the trials was carried out openly with the instrument reported by Moher et al. [12] , and there was no significant difference observed among the trials. Therefore, the result of the validity assessment was not considered in this pooled analysis.
Data abstraction
The following information was extracted from each report: study design, regimen details, allocated patients, cause of disease, race or ethnic group, Eastern Cooperative Oncology Group performance status (PS), pathological subtype, earlier chemotherapy, smoking status, EGFR protein expression, median follow-up, HRs for the whole study populations, and the year of reporting. Data were independently extracted from each report by X. S. and H. L., who were blinded to each other, using a standardized data recording form. After extraction, data were reviewed and compared by T.Z. and P.C. All data were checked for internal consistency, and any disagreements were resolved by discussion among the investigators. We also tried to contact principal investigators of the trials to confirm or update both published and unpublished data.
Statistical analysis
The primary endpoints in the pooled analysis were OS and PFS. The secondary endpoints were ORR and adverse events. Except adverse events, all analyses were conducted on an intention-to-treat (ITT) basis, and all randomly assigned patients were included in the analyses according to the allocated treatment. We looked for heterogeneity among the trials based on standard methods [13] . The DerSimonian and Laird Q statistic (Q test) was used to test for heterogeneity among trials [14] . Begg's funnel plots [15] and Egger's test [16] were used to detect possible publication bias. On the basis of the results of the Q test, we applied a randomeffects model (primarily) to estimate the summary HRs, ORs, and their 95% confidence intervals (CIs). If HRs or its 95% CIs could not be obtained from reports, crude logHR and its variance were calculated according to the method proposed by Parma et al. [17] . To reduce reading errors, original survival curves were digitalized and enlarged, and data extraction was based on reading off electronic coordinates for each point of interest. RCTs with useful information (n = 14)
Potentially relevant reports identified and screened for retrieval (n = 496)
Reasons: other malignancies, other treatment agent, nonrandomized trials, review articles, repeatedly reported, and retrospective analysis RCTs retrieved for more detailed evaluation (n = 37)
All statistical analyses were conducted with Review Manager V. 5.0.23 (Nordic Cochran Centre, Copenhagen, Denmark). All statistical tests were two sided, and P values of 0.05 were considered to be statistically significant.
Results
Trial flow
The flow chart of our study is shown in Fig. 1 . Ultimately, results of nine randomized phase II or III trials that had been published or presented at major international meetings were included in this analysis. Although we did not limit language in the process of searching, all the trials were published in English. All the 14 trials were RCTs and the results were based on ITT analysis except adverse events. There were three PIs who responded to our requests of confirming update of both published or unpublished data of the trials.
Characteristics of the fourteen trials
The characteristics of the 14 trials are listed in Table 1 . They included three phase III RCTs comparing with placebo as first-line therapy [18] [19] [20] , two phase II RCTs comparing with chemotherapy as first-line therapy [21, 22] , three phase III RCTs and one phase II RCT comparing with placebo as maintenance therapy [11, [23] [24] [25] , one phase III RCT comparing with placebo as second/thirdline therapy [26] , one phase III RCT and one phase II RCT comparing with chemotherapy as second/third-line therapy [27, 28] , one phase III RCT comparing with targeted drugs as second/third-line therapy [29] , and one phase II RCT comparing with targeted drugs as second/ third-line therapy [30] . In total, 7974 patients were randomized to receive erlotinib-based regimens (4114 patients) or other agent-based regimens (3860 patients).
Thirteen patients enrolled in one trial were excluded after randomization [18] . Further information about unpublished data was obtained by contacting the principal investigators. No potential sources of heterogeneity including sex, age, Eastern Cooperative Oncology Group PS, pathological subtype, earlier chemotherapy, and smoking status were associated with significant differences in outcomes.
Objective response rate
Eleven trials except for the trials conducted by Lee et al. [20] , Miller et al. [11] , and Perol et al. [25] reported ORR. The response rates ranged from 4.0 to 31.5% for the erlotinib-based regimens and from less than 1.0 to 40.0% for the other agent-based regimens ( Table 2) . As a firstline therapy, including nine trials and 5404 patients (erlotinib, n = 2710; other agent, n = 2694), the randomeffects model pooled estimate evaluated for ORR showed a similar ORR for erlotinib-based regimens (OR: 0.76; 95% CI: 0.53-1.08; P = 0.12). However, the test for heterogeneity shows a significant difference (I 2 = 66%, P = 0.02), therefore we had to carry out subgroup analysis. The subgroup analysis showed a similar ORR comparing with placebo (OR: 0.90; 95% CI: 0.74-1.09; P = 0.29) or chemotherapy (OR: 0.33; 95% CI: 0.64-17.36; P = 0.15), but an increased ORR comparing with placebo as maintenance therapy (OR: 0.47; 95% CI: 0.31-0.70; P < 0.01).
As second/third-line therapy including three trials and 1142 patients (erlotinib, n = 693; other agent, n = 449), the pooled estimate showed a similar ORR for erlotinib-based regimens (OR: 0.68; 95% CI: 0.15-3.10; P = 0.62). The test for heterogeneity also showed a significant difference (I 2 = 86%, P < 0.01). When compared with placebo, the subgroup analysis showed an increased ORR (OR: 0.10; 95% CI: 0.02-0.41; P < 0.01). However, compared with chemotherapy, there was a similar ORR between two arms (OR: 1.51; 95% CI: 0.85-2.70; P = 0.16).
With respect to all efficacy outcomes, random-effects (Figs 2-7) and fixed-effects models (data not shown) yielded virtually identical results. Neither a Begg's funnel plot nor a rank correlation test regarding response rate indicated the existence of publication bias (Z = -0.1, P = 1.00). The results of Egger' test was similar.
Progression-free survival
All 14 trials reported PFS ( Table 3) . As a first-line therapy, the random-effects model pooled estimate evaluated for PFS showed a similar PFS for erlotinib-based regimens (HR: 0.88; 95% CI: 0.76-1.03; P = 0.12). However, the test for heterogeneity showed a significant difference (I 2 = 85%, P < 0.01); therefore, we had to carry out subgroup analysis. The pooled estimate showed a similar PFS when compared with placebo (HR: 0.93; 95% CI: 0.85-1.01; P = 0.09), a decreased PFS compared with chemotherapy (HR: 1.55; 95% CI: 1.24-1.93; P < 0.01), but a prolonged PFS compared with placebo as maintenance therapy (HR: 0.71; 95% CI: 0.60-0.83; P < 0.01). As a second/third-line therapy including three trials, the pooled estimate showed a similar PFS for erlotinib-based regimens (HR: 0.75; 95% CI: 0.55-1.03; P = 0.08). The test for heterogeneity also showed a significant difference (I 2 = 75%, P = 0.02). The subgroup analysis showed a prolonged PFS compared with placebo (HR: 0.61; 95% CI: 0.51-0.73; P < 0.01), but a similar PFS compared with chemotherapy (HR: 0.89; 95% CI: 0.73-1.09; P = 0.26).
Neither a Begg's funnel plot nor a rank correlation test regarding response rate indicated the existence of publication bias (Z = 0.67, P = 0.50). The results of Egger' test was similar.
Overall survival
Eleven trials reported OS except for trials conducted by Miller et al. [11] , Perol et al. [25] , and Boyer et al. [30] ( Table 3 ). As first-line therapy including four trials, the random-effects model pooled estimate evaluated for OS showed a similar OS for erlotinib-based regimens (HR: 1.04;
95% CI: 0.89-1.22; P = 0.59). The test for heterogeneity showed a significant difference (I 2 = 65%, P = 0.01). The subgroup analysis showed a similar OS compared with placebo (HR: 1.02; 95% CI: 0.92-1.13; P = 0.73), or as maintenance therapy (HR: 0.87; 95% CI: 0.68-1.11; P = 0.22), but a decreased OS compared with chemotherapy (HR: 1.39; 95% CI: 0.99-1.94; P = 0.05).
As second/third-line therapy including three trials, the pooled estimate showed a similar OS for erlotinib-based regimens (HR: 0.88; 95% CI: 0.65-1.19; P = 0.42). The test for heterogeneity showed no significant difference (I 2 = 83%, P < 0.01). The subgroup analysis showed a prolonged OS compared with placebo (HR: 0.70; 95% CI: 0.58-0.84; P < 0.01), but a similar OS compared with chemotherapy (HR: 1.01; 95% CI: 0.92-1.11; P = 0.88).
Neither a Begg's funnel plot nor a rank correlation test regarding response rate indicated the existence of publication bias (Z = 0.73, P = 0.47). The results of Egger' test was similar. 299 Heterogeneity: 2 = 0.00; 2 = 0.09, df = 1 (P = 0.76); I 2 = 0% Heterogeneity: 2 = 0.00; 2 = 0.04; df = 1 (P = 0.85); I 2 = 0% Heterogeneity: 2 = 0.00; 2 = 0.59; df = 1 (P = 0.44); I 2 = 0% Heterogeneity: 2 = 0.25; 2 = 27.80; df = 5 (P < 0.0001); I 2 = 82% Test for overall effect: Z = 1.07 (P = 0.29) Test for overall effect: Z = 3.85 (P = 0.0001) Test for overall effect: Z = 3.65 (P = 0.0003) Test for overall effect: Z = 0.07 (P = 0.94) Lilenbaum et al. [21] Reck et al. [22] Cappuzzo et al. [ 
Adverse events
All 14 trials including 7261 patients provided results of adverse events. Reported toxicities were analyzed in only 12 trials except for the targeted drugs containing trials [29, 30] (Table 4 ). Grade 3/4 diarrhea (OR: 4.87; 95% CI: 3.19-7.44; P < 0.01), rash (OR: 28.94; 95% CI: 14.28-58.66; P < 0.01), and anemia (OR: 1.39; 95% CI: 1.06-1.82; P = 0.02) were significantly prominent in the erlotinib-based regimens, with all intertrial variability consistent with the play of chance. Compared with other agent-based regimens, erlotinib-based regimen did not increase the frequency of other adverse events. The heterogeneity test found no statistical significance for all adverse events.
On account of the significant heterogeneity (data not shown), we had to compare erlotinib with other targeted drugs, respectively. Compared with vandetanib, there was a similar ORR (OR: 1.00; 95% CI: 0.71-1.40; P = 0.98), PFS (HR: 0.98; 95.22% CI: 0.87-1.10; P = 0.72), OS (HR: 1.01; 95.08% CI: 0.89-1.16; P = 0.83), and the frequency of grade 3/4 adverse events (data not shown). Compared with PF299804, there was a decreased ORR (OR: 3.87; 95% CI: 1.27-11.81; P = 0.02), and shortened PFS (HR: 0.58; 95% CI: 0.49-0.95; P = 0.02). At the same time, erlotinib did not increase the frequency of grade 3/4 adverse events, except for diarrhea (OR: 0.25; 95% CI: 0.07-0.91; P = 0.04).
Discussion
The EGFR family is part of a complicated signaltransduction network that is a key to several critical cellular processes [31] . Overexpression of EGFR is common in NSCLC and is associated with poor survival. During the last decade, the treatment for patients with advanced NSCLC has improved as a result of the invention of novel, effective, agents targeting the EGFR pathway, such as gefitinib and erlotinib. To date, the reports of several phase II/III trials showed inconsistent results on clinical outcomes with regard to ORR, PFS, and OS. Thus, the impact of erlotinib-based regimens on the survival of advanced NSCLC patients compared with other agent-based regimens remained undetermined.
In this pooled analysis, we identified 14 RCT trials including 7974 patients, and the largest accounted for 1240 randomly assigned patients. However, because of the difference of the schedule of treatment and controlled regimens, the heterogeneity between trials was statistically significant. Thus, we must explain the results with caution and we had to carry out subgroup analysis according to the schedule of treatment and controlled regimens. As first-line therapy was compared with chemotherapy, there was a decreased PFS (HR: 1.55; 95% CI: 1.24 to 1.93; P < 0.01) and OS (HR: 1.39; 95% CI: 0.99-1.94; P = 0.05). As maintenance therapy was compared with placebo, erlotinib-based regimens Shepherd et al. [26] Herbst et al. [27] Vamvakas et al. [28] Total events Total events
Total events
Heterogeneity: not applicable Heterogeneity: 2 = 0.00; 2 = 0.00; df = 1 (P = 0.98); I 2 = 0% Heterogeneity: 2 = 1.51; 2 = 13.97; df = 2 (P = 0.0009); I 2 = 86% Test for overall effect: Z = 3.18 (P = 0.001) Test for overall effect: Z = 1.4 (P = 0.16) Test for overall effect: Z = 0.50 (P = 0.62) Test for subgroup differences: not applicable significantly increased ORR (OR: 0.47; 95% CI: 0.31-0.70; P < 0.01), prolonged PFS (HR: 0.71; 95% CI: 0.60-0.83; P < 0.01), but did not improve OS (HR: 0.87; 95% CI: 0.68-1.11; P = 0.22). As second/third-line therapy was compared with placebo, erlotinib-based regimens also significantly increased ORR (OR: 0.10; 95% CI: 0.02-0.41; P < 0.01), prolonged PFS (HR: 0.61; 95% CI: 0.51-0.73; P < 0.01), and improved OS (HR: 0.70; 95% CI: 0.58-0.84; P < 0.01). However, as second/ third-line therapy was compared with chemotherapy, the outcomes were similar between two arms. When compared with PF299804, there was a decreased ORR (OR: 3.87; 95% CI: 1.27-11.81; P = 0.02), and shortened PFS (HR: 0.58; 95% CI: 0.49-0.95; P = 0.02). Thus, we believe that as first-line therapy, we should prefer chemotherapy to erlotinib; as maintenance therapy, we should prefer erlotinib to placebo; as second/third-line therapy, we should prefer erlotinib or chemotherapy to best supportive care in some patients with good PS status. No matter compared with placebo or chemother-apy, the results did not show that erlotinib-based regimens could increase ORR and improve PFS and OS as first-line therapy.
An unexpected finding was an increased incidence in anemia with the erlotinib combination. This increase was mostly due to the result reported during the trial conducted by Gatzemeier et al. [18] . The other four trials that reported the incidence of anemia did not show any difference between the two groups. As it is believed that erlotinib has no effect on bone marrow, and up to now, there is no experimental or clinical evidence of erlotinib inducing anemia, we believed the increased incidence reported by Gatzemeier et al. [18] was just an accident and pointless. Neither did the Begg's funnel plot for publication bias nor did the heterogeneity test yield a significant result. As the results based on the fixed-effect model were similar to the results based on the random-effect model, we did not show the results based on the fixed-effect model. Heterogeneity: 2 = 0.00; 2 = 1.94, df = 2 (P = 0.38); I 2 = 0% Heterogeneity: 2 = 0.00; 2 = 0.16, df = 1 (P = 0.69); I 2 = 0%
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Cappuzzo et al. [22] Miller et al. [11] Mok et al. [24] Perol et al. [25] Lilenbaum et al. [21] Reck et al. [22] Test for overall effect: Herbst et al. [27] Vamvakas et al. [28] Heterogeneity: not applicable Heterogeneity: 2 = 0.00; 2 = 0.26; df = 1 (P = 0.61); I 2 = 0% Heterogeneity: 2 = 0.11; 2 = 30.23; df = 2 (P < 0.00001); Test for overall effect: Z = 0.54 (P = 0.59) Test for subgroup differences: 2 = 11.00. df = 2 (P = 0.004). I 2 = 81.8%
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Log (risk ratio)
Risk ratio IV, random, 95% CI SE Weight Risk ratio IV, random, 95% CI τ τ χ χ χ Overall survival with erlotinib-based regimens compared with other agent-based regimens as second/third-line therapy. The heterogeneity test yielded a significant result (P = 0.18). CI, confidence interval. However, there were still several limitations in this pooled analysis. First, this analysis was based on literature abstract-based data, not individual patient data (IPD). An IPD meta-analysis would give a more robust estimate of the association but it would take a long time to obtain data [32] . However, the analysis based on published trials is an accepted method, and offers the most comprehensive insight into erlotinib-based regimens as soon as possible and may help physicians and their patients worldwide to make a better informed decision regarding the most appropriate therapy. A recently reported analysis confirmed that IPD and literature abstract-based metaanalyses did not differ substantially in their outcome [33] . Second, although we included 14 trials, there were only one to three trials in each subgroup [34] [35] [36] [37] [38] [39] . However, all the 14 trials were RCTs, and all the results except for adverse events were based on ITT analysis. Therefore, we considered that our pooled analysis based on these trials is believable. Third, possible publication bias is also a potential threat in our study, although we did not detect it statistically.
In conclusion, this is the first published pooled analysis, to our knowledge, of randomized trials of erlotinib-based regimens versus other agent-based regimens in treating advanced NSCLC. Although there are some limitations, our findings demonstrate that erlotinib-based regimens significantly increase ORR and improve PFS as a first-line maintenance therapy or as a second/third-line therapy compared with placebo. Thus, the use of erlotinib may be a new effective therapy in treating advanced NSCLC as first-line maintenance therapy or second/third-line therapy compared with best supportive care. 
